3.020USD+3.42%Mkt Cap: 135.64M USDP/E: —Last update: 2026-05-26
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap135.64M USD
Enterprise Value107.22M USD
Revenue (TTM)8.00K USD
Gross Profit8.00K USD
Net Income (TTM)-32.15M USD
Revenue/Share0.0000 USD
Last Price3.020 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees25
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.83
PEG—
EV/EBITDA-3.12
EV/Revenue13402.50
P/S16366.75
P/B9.54
EPS (TTM)-0.85
EPS (Forward)-0.76
52W Range
2.29012% of range8.535
52W High8.535 USD
52W Low2.290 USD
Profitability
Gross Margin100.00%
Oper. Margin-432112.50%
EBITDA Margin0.00%
Profit Margin-401812.50%
ROE-278.46%
ROA-168.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.27M USD
CapEx (TTM)1.10M USD
FCF Margin-194795.31%
FCF Yield-11.49%
Net Debt-23.71M USD
Net Debt/EBITDA0.69
Balance Sheet
Debt/Equity0.15
Current Ratio3.68
Quick Ratio3.60
Book Value/Sh0.3060 USD
Cash/Share0.5840 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)17.50 USD
Target Range10.00 USD – 31.00 USD
# Analysts6
Ownership
Shares Out.44.84M
Float36.53M
Insiders10.74%
Institutions30.68%
Short Interest
Short Ratio15.2d
Short % Float7.23%
Short % Out.7.02%
Shares Short3.15M
Short (prev mo.)3.14M
Technical
SMA 502.679 (+12.7%)
SMA 2003.773 (-20.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)158.61K
Avg Vol (10d)189.30K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—